<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="669">
  <stage>Registered</stage>
  <submitdate>30/08/2005</submitdate>
  <approvaldate>30/08/2005</approvaldate>
  <nctid>NCT00141648</nctid>
  <trial_identification>
    <studytitle>Chemotherapy and Radiotherapy for Osteolymphoma</studytitle>
    <scientifictitle>A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALLG LY-02</secondaryid>
    <secondaryid>TROG 99.04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteolymphoma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Treatment: other - Radiotherapy

Experimental: 1 - Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.


Treatment: drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2

Treatment: other: Radiotherapy
Total 45 Gy in 25 fractions

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Survival. The time from registration to the date of death</outcome>
      <timepoint>Main analysis when accrual is complete at approx. 10 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to local or regional failure. Measured from registration.</outcome>
      <timepoint>Main analysis when accrual is complete at approx. 10 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pathological fracture rate. Measured from registration.</outcome>
      <timepoint>Main analysis when accrual is complete at approx. 10 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed non-Hodgkin's lymphoma in a bony site

          -  Limited extraosseous disease

          -  Ann Arbor stage IE

          -  Age &gt;17

          -  ECOG performance status &lt;3

          -  Expected survival &gt; 6 months

          -  Patients capable of childbearing are using adequate contraception.

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous radiotherapy

          -  Previous malignancy

          -  Medically unfit to undergo treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>70</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>The Wesley Radiation Oncology Pty Ltd - Auchenflower</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <hospital>Mater QRI - South Brisbane</hospital>
    <hospital>North Queensland Oncology Service - Townsville</hospital>
    <hospital>East Coast Cancer Centre, John Flynn Hospital - Tugun</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Launceston General Hospital - Launceston</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Andrew Love Cancer Care Centre, Geelong Hospital - Geelong</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>1871 - Liverpool</postcode>
    <postcode>2310 - Newcastle</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode> - Wollongong</postcode>
    <postcode>4006 - Auchenflower</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4810 - Townsville</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Leukaemia and Lymphoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Radiation Oncology Lymphoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Wesley Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is intended to determine the results obtained when standard treatment for Non
      Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients
      in the study undergo a detailed assessment, then treatment with chemotherapy and
      radiotherapy, followed by close monitoring.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00141648</trialwebsite>
    <publication>Christie DR, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J. 2007 Oct;37(10):680-6.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Christie, FRANZCR</name>
      <address>East Coasr Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>